Spero Therapeutics, INC 8-K filings

Spero Therapeutics announced FDA approval for Utebzi, a $105 million financing deal, and a new licensing agreement for its SP001 program, extending cash runway into late 2029.

Spero Therapeutics has entered into an exclusive license agreement for SP001 (IBI355), a third-generation anti-CD40L antibody from Innovent Biologics, and secured $105 million in non-dilutive financing.

Spero Therapeutics shareholders approved a doubling of authorized common stock to 240 million shares and the 2026 Stock Incentive Plan at the annual meeting.

Spero Therapeutics announced strong Q4 and full-year 2025 financial results, driven by collaboration revenue, and confirmed the FDA's PDUFA date for tebipenem HBr as June 18, 2026.

Spero Therapeutics announced a board member's resignation and the conclusion of an SEC investigation with no enforcement action recommended.

Spero Therapeutics announced its partner GlaxoSmithKline resubmitted the New Drug Application for tebipenem HBr, triggering a $25 million milestone payment.

Spero Therapeutics announced third quarter 2025 financial results, highlighted by positive Phase 3 PIVOT-PO trial data for tebipenem HBr, its planned FDA submission by GSK, and the discontinuation of the SPR720 program.

Spero Therapeutics announced positive Phase 3 trial results for its oral antibiotic tebipenem HBr, extending its cash runway into 2028, while suspending its SPR720 program.

Spero Therapeutics, Inc. announced that its stockholders approved all proposals at the 2025 Annual Meeting held on June 12, 2025, including the re-election of three Class II directors, ratification of auditors, approval of executive compensation, and an increase of 3,000,000 shares for its 2017 Stock Incentive Plan.

Spero Therapeutics and its partner GSK announced that their pivotal Phase 3 PIVOT-PO trial for tebipenem HBr, an investigational oral treatment for complicated urinary tract infections, met its primary endpoint and was stopped early due to efficacy, paving the way for a planned FDA filing in the second half of 2025.

Spero Therapeutics reports Q1 2025 financial results and provides a business update, highlighting the upcoming interim analysis of the Phase 3 PIVOT-PO trial for tebipenem HBr.

Spero Therapeutics names Esther Rajavelu as President and CEO, effective May 2, 2025, succeeding Sath Shukla, who departs from the company and the Board of Directors.

Spero Therapeutics reports its Q4 and full year 2024 financial results, highlighting a net loss but anticipating sufficient cash runway into Q2 2026, while also providing updates on its clinical programs.

Spero Therapeutics has been notified by Nasdaq that its common stock price fell below the required $1.00 minimum, potentially leading to delisting if not rectified by August 25, 2025.

Spero Therapeutics has appointed an interim CEO and board chair following a Wells Notice from the SEC, while also reporting progress on its Phase 3 trial for Tebipenem HBr and providing a cash runway update.

Spero Therapeutics reported its third quarter 2024 financial results and provided a business update, including progress on its tebipenem HBr trial and a cash runway into mid-2026.

Spero Therapeutics is restructuring its operations, including a 39% workforce reduction, after a Phase 2a trial for SPR720 failed to meet its primary endpoint, but the company has extended its cash runway into mid-2026.

Spero Therapeutics updated its investor presentation, highlighting progress on its clinical programs for SPR720, tebipenem HBr, and SPR206, with key data readouts expected in the near term.

Spero Therapeutics reported its second quarter 2024 financial results and provided a business update, highlighting the completion of enrollment in a Phase 2a trial for SPR720 and progress in the Phase 3 trial for tebipenem HBr.

Spero Therapeutics' stockholders approved an amendment to the 2017 Stock Incentive Plan, increasing the authorized shares by 3,000,000, at the company's annual meeting on May 29, 2024.

Spero Therapeutics announced its first quarter 2024 financial results and provided updates on its clinical programs, including progress on SPR720, tebipenem HBr, and SPR206.

Spero Therapeutics has scheduled its 2024 Annual Meeting of Stockholders for May 29, 2024, to be held entirely online.

Spero Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting a net income of $22.8 million for the year and progress across its clinical programs.

Spero Therapeutics' Chief Legal Officer, Tamara Joseph, is stepping down effective March 6, 2024, with a separation and consulting agreement in place.